📊 FATE Key Takeaways
Is Fate Therapeutics Inc. (FATE) a Good Investment?
FATE is a pre-revenue stage biotech company burning significant cash (-$106.1M operating CF) with collapsing revenues (-51.2% YoY) and extreme negative margins exceeding -2000%. The company faces a critical cash runway issue despite adequate liquidity, requiring substantial additional funding or clinical/commercial success to remain viable.
Fate Therapeutics shows weak fundamentals driven by a steep revenue decline, extremely negative operating and net margins, and heavy cash burn relative to its small revenue base. The balance sheet is still a meaningful offset, with strong liquidity, low leverage, and substantial equity supporting near-term operations. Overall, the company appears financially stable in the short term but fundamentally weak until it can improve commercialization, partnership revenue durability, or expense efficiency.
Why Buy Fate Therapeutics Inc. Stock? FATE Key Strengths
- Strong liquidity position with 5.79x current ratio and $46.6M cash on hand
- Relatively low leverage with 0.07x debt-to-equity ratio providing financial flexibility
- Moderate long-term debt burden of only $14.0M limits near-term refinancing pressure
- Strong liquidity with current and quick ratios of 5.79x
- Low leverage with debt/equity of 0.07x and only $14.00M in long-term debt
- Solid equity base of $207.18M provides near-term balance sheet support
FATE Stock Risks: Fate Therapeutics Inc. Investment Risks
- Severe cash burn of $112.1M free cash flow with only ~5 quarters of cash runway at current burn rate
- Revenue collapse of 51.2% YoY indicating clinical/commercial development setbacks or failed pipeline programs
- Persistent unprofitability with operating losses of $147.7M and negative 2222% operating margin reflects fundamental business model challenges
- Dilution risk from required capital raises to fund continued R&D and operations
- Revenue fell 51.2% YoY, indicating poor growth quality and weak top-line stability
- Operating margin of -2222.4% and net margin of -2051.1% reflect an unsustainable cost structure
- Free cash flow of -$112.04M and operating cash flow of -$106.08M point to continued cash runway pressure if losses persist
Key Metrics to Watch
- Quarterly cash burn trends and cash runway to next major catalysts
- Revenue trends - stabilization or further deterioration signals pipeline success/failure
- Operating cash flow and path to profitability timeline from management guidance
- Clinical trial progress and regulatory milestones for lead programs
- Quarterly revenue trajectory and quality of collaboration/product revenue
- Cash burn rate versus cash and equivalents balance
Fate Therapeutics Inc. (FATE) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.79x current ratio provides a solid financial cushion.
FATE Profit Margin, ROE & Profitability Analysis
FATE vs Healthcare Sector: How Fate Therapeutics Inc. Compares
How Fate Therapeutics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Fate Therapeutics Inc. Stock Overvalued? FATE Valuation Analysis 2026
Based on fundamental analysis, Fate Therapeutics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Fate Therapeutics Inc. Balance Sheet: FATE Debt, Cash & Liquidity
FATE Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Fate Therapeutics Inc.'s revenue has declined by 76% over the 5-year period, indicating business contraction. The most recent EPS of $-1.64 indicates the company is currently unprofitable.
FATE Revenue Growth, EPS Growth & YoY Performance
FATE Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $1.7M | -$32.3M | $-0.27 |
| Q2 2025 | $1.9M | -$34.1M | $-0.29 |
| Q1 2025 | $1.6M | -$37.6M | $-0.32 |
| Q3 2024 | $1.9M | -$18.9M | $-0.40 |
| Q2 2024 | $933.0K | -$18.9M | $-0.33 |
| Q1 2024 | $1.9M | -$18.9M | $-0.19 |
| Q3 2023 | $1.9M | -$18.9M | $-0.46 |
| Q2 2023 | $933.0K | -$18.9M | $-0.54 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Fate Therapeutics Inc. Dividends, Buybacks & Capital Allocation
FATE SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Fate Therapeutics Inc. (CIK: 0001434316)
📋 Recent SEC Filings
❓ Frequently Asked Questions about FATE
What is the AI rating for FATE?
Fate Therapeutics Inc. (FATE) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are FATE's key strengths?
Claude: Strong liquidity position with 5.79x current ratio and $46.6M cash on hand. Relatively low leverage with 0.07x debt-to-equity ratio providing financial flexibility. ChatGPT: Strong liquidity with current and quick ratios of 5.79x. Low leverage with debt/equity of 0.07x and only $14.00M in long-term debt.
What are the risks of investing in FATE?
Claude: Severe cash burn of $112.1M free cash flow with only ~5 quarters of cash runway at current burn rate. Revenue collapse of 51.2% YoY indicating clinical/commercial development setbacks or failed pipeline programs. ChatGPT: Revenue fell 51.2% YoY, indicating poor growth quality and weak top-line stability. Operating margin of -2222.4% and net margin of -2051.1% reflect an unsustainable cost structure.
What is FATE's revenue and growth?
Fate Therapeutics Inc. reported revenue of $6.6M.
Does FATE pay dividends?
Fate Therapeutics Inc. does not currently pay dividends.
Where can I find FATE SEC filings?
Official SEC filings for Fate Therapeutics Inc. (CIK: 0001434316) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is FATE's EPS?
Fate Therapeutics Inc. has a diluted EPS of $-1.15.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is FATE a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Fate Therapeutics Inc. has a SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is FATE stock overvalued or undervalued?
Valuation metrics for FATE: ROE of -65.8% (sector avg: 15%), net margin of -2,051.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy FATE stock in 2026?
Our dual AI analysis gives Fate Therapeutics Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is FATE's free cash flow?
Fate Therapeutics Inc.'s operating cash flow is $-106.1M, with capital expenditures of $6.0M. FCF margin is -1,685.8%.
How does FATE compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -2,051.1% (avg: 12%), ROE -65.8% (avg: 15%), current ratio 5.79 (avg: 2).